Condition 1: Schizophrenia. Condition 2: Depressive episode. The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted In typical mild, moderate, or severe depressive episodes, the patient suffers from lowering of mood, reduction of energy, and decrease in activity. Capacity for enjoyment, interest, and concentration is reduced, and marked tiredness after even minimum eff
Conditions
Interventions
Intervention 1: treatment (intervention) group receives aromatherapy (to get fragrances, 96% cotton impregnated with 3 drops of clove extract is placed at a distance of 20 cm from the patient's nose o
Prevention
treatment (intervention) group receives aromatherapy (to get fragrances, 96% cotton impregnated with 3 drops of clove extract is placed at a distance of 20 cm from the patient's nose on collar pins fo
control group : receiving routine treatment
Sponsors
Vice president for Research and Technology of Semnan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age between 20 and 50 years; no allergy to clove scent; receiving 6 sessions of electroconvulsive therapy. Exclusion criteria: no consent of patient to continue the study; any change in the patient situation that affects the process of treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Memory status. Timepoint: Before the first and after the third and sixth sessions of electrocovulsive therapy. Method of measurement: Wechsler Memory Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of total antioxidant capacity (FRAP). Timepoint: Before starting ECT and after the last session. Method of measurement: Ferric reducing antioxidant power(FARP.;Level of malondialdehyde (MDA). Timepoint: Before starting ECT and after the last session. Method of measurement: Thiobarbituric acid (TBA).;Level of cortisol. Timepoint: Before starting ECT and after the last session. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehri Ansari- Niaki
Semnan University of Medcial Sciences
Outcome results
None listed